AKBA
Akebia Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
FDA Approved
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AKBA
Akebia Therapeutics, Inc.
A biopharmaceutical company that develops novel therapeutics for patients with kidney disease
245 First Street, Cambridge, MA 02142
--
Akebia Therapeutics, Inc., was legally incorporated in Delaware on February 27, 2007. The company is a biopharmaceutical company dedicated to the research and development of novel biological proprietary therapies based on hypoxia-inducible factors and the commercial application of products required by patients with kidney disease. HIF is the primary regulator of new mechanisms of erythropoiesis and potential anemia treatment in the human body. Akebia's lead product candidate, AKB-6548, as a once-daily oral product, has successfully completed a Phase 2 proof-of-concept. Studies have shown that AKB-6548 can safely and effectively increase hemoglobin levels in patients with secondary anemia and chronic kidney disease without the need for dialysis.
Earnings Call
Q1/2025
Estimate EPS-0.04
Actual EPS0.03
Estimate Revenue44.53M
Actual Revenue57.34M
Akebia's Q1 2025 Earnings Call: Unpacking Contradictions in Vafseo Adoption, Auryxia Sales, and NDD Trial Progress
May 19,2025 08:28
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.03
Actual EPS0
Estimate Revenue47.24M
Actual Revenue62.47M
Akebia's Q2 2025 Earnings Call: Unpacking Contradictions in Vafseo Trends, Auryxia Revenue, and FDA Strategies
Aug 07,2025 07:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AKBA has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected -0.02, beating expectations. The chart below visualizes how AKBA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AKBA has released its 2025 Q3 earnings report, with revenue of 58.77M, reflecting a YoY change of 57.01%, and net profit of 540.00K, showing a YoY change of 102.69%. The Sankey diagram below clearly presents AKBA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
